NVR Free cash flow decreased by 23.2% to $334.82M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 66.8%, from $200.72M to $334.82M. Over 4 years (FY 2021 to FY 2025), Free cash flow shows a downward trend with a -2.7% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $189.25M | $455.95M | $254.17M | $305.27M | $133.19M | $602.48M | $810.74M | $312.81M | $19.95M | $651.00M | $489.36M | $137.48M | $226.26M | $350.05M | $631.46M | $200.72M | $26.80M | $433.26M | $436.03M | $334.82M |
| QoQ Change | — | +140.9% | -44.3% | +20.1% | -56.4% | +352.4% | +34.6% | -61.4% | -93.6% | >999% | -24.8% | -71.9% | +64.6% | +54.7% | +80.4% | -68.2% | -86.6% | >999% | +0.6% | -23.2% |
| YoY Change | — | — | — | — | -29.6% | +32.1% | +219.0% | +2.5% | -85.0% | +8.1% | -39.6% | -56.1% | >999% | -46.2% | +29.0% | +46.0% | -88.2% | +23.8% | -30.9% | +66.8% |